U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C26H32ClFO5
Molecular Weight 478.981
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOBETASONE BUTYRATE

SMILES

[H][C@@]12C[C@H](C)[C@](OC(=O)CCC)(C(=O)CCl)[C@@]1(C)CC(=O)[C@@]3(F)[C@@]2([H])CCC4=CC(=O)C=C[C@]34C

InChI

InChIKey=FBRAWBYQGRLCEK-AVVSTMBFSA-N
InChI=1S/C26H32ClFO5/c1-5-6-22(32)33-26(21(31)14-27)15(2)11-19-18-8-7-16-12-17(29)9-10-23(16,3)25(18,28)20(30)13-24(19,26)4/h9-10,12,15,18-19H,5-8,11,13-14H2,1-4H3/t15-,18-,19-,23-,24-,25-,26-/m0/s1

HIDE SMILES / InChI

Molecular Formula C26H32ClFO5
Molecular Weight 478.981
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Clobetasone is a corticosteroid used in dermatology, for treating such skin inflammation as seen in eczema, psoriasis and other forms of dermatitis, and ophthalmology. Topical clobetasone butyrate has shown minimal suppression of the Hypothalamic-pituitary-adrenal axis. It is available as clobetasone butyrate under the brand names Eumosone or Eumovate both manufactured by GlaxoSmithKline. Trimovate also contains Oxytetracycline, an antibiotic, and nystatin, an antifungal. Clobetasone butyrate is classed as a moderately potent topical corticosteroid. Clobetasone butyrate relieves the symptoms of a flare-up by reducing inflammation, itching and redness. It is not a cure for the condition, but it will help to relieve the symptoms. Although less potent topical steriods are often preferred for use in children, a short course of clobetasone butyrate may be prescribed for a child with severe eczema on the arms or legs. Short courses of clobetasone butyrate may also be prescribed for the treatment of psoriasis for areas such as the face, or the inside of elbows and behind the knees. In ophthalmology, clobetasone butyrate 0.1% eye drops have been shown to be safe and effective in the treatment of dry eyes in Sjögren's Syndrome.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
0.19 nM [EC50]
6080.0 nM [IC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
EUMOVATE CREAM
Palliative
EUMOVATE CREAM
Palliative
EUMOVATE CREAM
Palliative
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
Eumovate (clobetasone butyrate 0.05%) should be applied thinly and evenly to the affected area(s) of skin up to 2 times a day
Route of Administration: Topical
In Vitro Use Guide
Clobetasone butyrate depressed proliferation of cell strains derived from normal human foreskin at 10 ug/ml
Substance Class Chemical
Record UNII
8U0H6XI6EO
Record Status Validated (UNII)
Record Version